Neutral impactStocks

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

CNBC-TV18 1 hr ago·18 Sept 2026, 7:03 am

Bernstein said Novartis' decision to discontinue VHB937 for amyotrophic lateral sclerosis (ALS) on September 16 improves the commercial landscape for Zydus Lifesciences' Usnoflast.

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Zydus Lifesciences (ZYDUSLIFE).
  • Category: Stocks.

Why it matters

A routine update for Zydus Lifesciences. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC-TV18.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future | Zydus Lifesciences (ZYDUSLIFE)